Document Type
Journal Article
Publisher
Elsevier Inc
Place of Publication
United States
School
School of Medical and Health Sciences
RAS ID
24977
Funders
CogState Ltd
Hollywood Private Hospital
Sir Charles Gairdner Hospital
CSIRO
Science and Industry Endowment Fund
Alzheimer's Australia
WA Dept. of Health
Brightfocus
McCusker Alzheimer's Research Foundation
Abstract
Introduction
A blood-based biomarker panel to identify individuals with preclinical Alzheimer's disease (AD) would be an inexpensive and accessible first step for routine testing.
Methods
We analyzed 14 biomarkers that have previously been linked to AD in the Australian Imaging Biomarkers lifestyle longitudinal study of aging cohort.
Results
Levels of apolipoprotein J (apoJ) were higher in AD individuals compared with healthy controls at baseline and 18 months (P =.0003) and chemokine-309 (I-309) were increased in AD patients compared to mild cognitive impaired individuals over 36 months (P =.0008).
Discussion
These data suggest that apoJ may have potential in the context of use (COU) of AD diagnostics, I-309 may be specifically useful in the COU of identifying individuals at greatest risk for progressing toward AD. This work takes an initial step toward identifying blood biomarkers with potential use in the diagnosis and prognosis of AD and should be validated across other prospective cohorts.
DOI
10.1016/j.dadm.2017.04.003
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Comments
Gupta, V. B., Hone, E., Pedrini, S., Doecke, J., O'Bryant, S., James, I., ... & Masters, C. L. (2017). Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 8(1). 60-72.
https://doi.org/10.1016/j.dadm.2017.04.003